Skip to main content
. 2020 Nov 20;112(1):314–322. doi: 10.1111/cas.14693

TABLE 1.

Patients’ characteristics

Non‐FLT3 amp (n = 1993) FLT3 amp (n = 85) P a P b
Low amp (n = 40, 1.9%) n (%) High amp (n = 45, 2.2%) n (%)
Age
Median, (range) (y) 64 (21‐88) 65 (35‐84) 65 (32‐83) .85 .88
Gender
Male 1103 (55.3) 29 (72.5) 21 (46.7) .56 .02
Female 90 (44.7) 11 (28.5) 24 (54.3)
Primary site
Right colon 619 (31.1) 11 (27.5) 13 (28.9) <.01 .06
Left colon 718 (36.0) 15 (37.5) 12 (71.1)
Rectum 628 (31.5) 10 (25.0) 20 (44.4)
Unknown 28 (1.4) 4 (10.0) 0 (0.0)
Histology (grade)
Grade 1 543 (27.2) 8 (20.0) 9 (20.0) .20 .75
Grade 2 1201 (60.3) 26 (65.0) 33 (73.3)
Grade 3 94 (4.7) 3 (7.5) 1 (2.2)
Others 23 (5.2) 2 (5.0) 1 (2.2)
Unknown 52 (2.6) 1 (2.5) 1 (2.2)
RAS
Wild‐type 1149 (57.2) 16 (40.0) 28 (63.2) .12 .04
Mutant 844 (42.8) 24 (60.0) 17 (37.8)
BRAF V600E
Wild‐type 1869 (93.8) 39 (97.5) 45 (100.0) .03 .29
Mutant 124 (6.2) 1 (2.5) 0 (0.0)
PIK3CA
Wild‐type 1763 (88.4) 36 (90.0) 44 (97.8) .14
Mutant 230 (7.3) 4 (10.0) 1 (2.2) .13
ERBB2
Non‐Amp 1938 (97.2) 39 (97.5) 45 (93.3) .37 .29
Amp (CN ≥ 7.0) 55 (2.8) 1 (5.0) 0 (0.0)
TP53
Wild‐type 711 (35.7) 11 (27.5) 11 (24.5) .16 .75
Mutant 1282 (64.3) 29 (72.5) 34 (75.5)
BRCA1
Wild‐type 1859 (93.2) 31 (77.5) 38 (80.0) <.01 .41
Mutant 134 (6.8) 9 (22.5) 7 (15.6)
BRCA2
Wild‐type 1731 (86.9) 30 (75.0) 44 (97.8) <.01 <.01
Mutant 262 (13.1) 0 (0.0) 0 (0.0)
Amp (CN ≥ 7.0) 0 (0.0) 10 (25.0) 1 (2.2)

Abbreviations: amp, amplification; CN, copy number.

a

P‐values were calculated including 3 cohorts (Non‐FLT3 amp and FLT3 amp: Low amp and high amp) using Pearson chi‐square test.

b

P‐values were calculated between 2 cohorts (Low amp and high amp) by Pearson chi‐square test.